Log In Sign up
The largest database of trusted experimental protocols

Recombinant human interleukin 2 il 2

Manufactured by R&D Systems
Visit Supplier
Sourced in United States

Recombinant human interleukin 2 (IL-2) is a protein produced in a laboratory setting. It is a cytokine that plays a role in the immune system.

Automatically generated - may contain errors

Lab products found in correlation

Peptidoglycan pgn, by Merck Group (1 mentions) Rpmi 1640 medium, by Merck Group (1 mentions) Histopaque 1077, by Merck Group (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Ficoll hypaque, by Cytiva (1 mentions) Anti human cd3 antibody, by Thermo Fisher Scientific (1 mentions) Anti human cd28 antibody, by Thermo Fisher Scientific (1 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions) Ms column, by Miltenyi Biotec (1 mentions) Penicillin and streptomycin, by Solarbio (1 mentions) Nk cell activation expansion kit, by Miltenyi Biotec (1 mentions) Nk isolation kit, by Miltenyi Biotec (1 mentions) Nk macs, by Miltenyi Biotec (1 mentions) Recombinant human retronectin, by Takara Bio (1 mentions)

3 protocols using recombinant human interleukin 2 il 2

1

Recombinant IL-2 Immunomodulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human interleukin 2 (IL-2) was purchased from R&D systems (Minneapolis, MN). Peptidoglycan (PGN), Histopaque®−1077, RPMI-1640 medium and CsA were from Sigma-Aldrich (St Louis, MO).
Veretennikova A, & Chang T.L. (2022). Chlamydia trachomatis Enhances HIV Infection of Non-Activated PBMCs. EC microbiology, 18(4), 13-17.
+ Open protocol
+ Expand
2

PBMC Isolation and CD4+ T Cell Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of patients with ITP and healthy control subjects with Ficoll-Hypaque centrifugation (Amersham Biosciences, Piscataway, NJ). CD4+ T cells were sorted by using magnetic beads and MS Columns (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the isolated cells was >90% as measured by flow cytometry.
PBMCs or sorted CD4+ T cells were cultured in RPMI 1640 medium (Life Technologies, Paisley, United Kingdom) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Grand Island, NY) and 1% penicillin and streptomycin (Solarbio, Beijing, China). Cells were stimulated with recombinant human interleukin-2 (IL-2; 5 ng/mL; R&D Systems, Minneapolis, MN), anti-human CD3 antibodies (1 ng/mL; eBioscience, San Diego, CA), and anti-human CD28 antibodies (1 ng/mL; eBioscience) and incubated for 72 hours (37°C, 5% carbon dioxide).24 (link)
Han P., Hou Y., Zhao Y., Liu Y., Yu T., Sun Y., Wang H., Xu P., Li G., Sun T., Hu X., Liu X., Li L., Peng J., Zhou H, & Hou M. (2021). Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood, 138(8), 674-688.
+ Open protocol
+ Expand
3

Isolation and Expansion of NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor's buffy coat or leukapheresis (OPBG Hospital, Rome, Italy) by a density-gradient technique (Ficool-Histopaque (Eurobio;France); the healthy donors had signed a written informed consent, in accordance with rules set by the Institutional Review Board of OPBG (Approval of Ethical Committee N_969/2015 prot. N_669LB). CD56 + CD3 neg NK cells, isolated with an NK isolation Kit (Miltenyi Biotec, Inc., San Diego, CA, USA), and expanded with NK Cell Activation/Expansion Kit (adapted protocol from Navarro et al. 46 ) (Miltenyi Biotec, Inc., San Diego, CA, USA) and recombinant human interleukin 2 (IL2, 500 U/ml; R&D; USA) or recombinant interleukin 15 (IL15 10 U/ml; R&D; USA). Activated NK cells were transduced in 24-well plates pre-coated with recombinant human RetroNectin (Takara-Bio. Inc; Japan) using retroviral supernatant. Enriched NK cells were cultured in GMP-compliant media (NK MACS Miltenyi Biotec, Inc., San Diego, CA, USA).
Quintarelli C., Sivori S., Caruso S., Carlomagno S., Falco M., Boffa I., Orlando D., Guercio M., Abbaszadeh Z., Sinibaldi M., Di Cecca S., Camera A., Cembrola B., Pitisci A., Andreani M., Vinti L., Gattari S., Del Bufalo F., Algeri M., Li Pira G., Moseley A., De Angelis B., Moretta L, & Locatelli F. (2020). Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia, 34(4).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!